Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Since there have been no published dose-response studies investigating the effective analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia, the investigators propose a study primarily examining the effect on 24 hour post-Cesarean delivery opioid consumption of using either a placebo, 0.25% ropivacaine, 0.5% ropivacaine, or 0.75% ropivacaine for TAP blocks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• ASA II-III patient

• > 18 years of age who is pregnant

• presenting for a cesarean delivery via Pfannenstiel incision who is eligible to receive a spinal anesthetic with 0.75% bupivacaine and fentanyl and whose is not eligible to receive intrathecal morphine due to a BMI >40 kg/m2.

Exclusion Criteria:

• < 18 years of age

• contraindication to placement of a spinal anesthetic

• contraindication to use of non-steroidal anti-inflammatory drugs (NSAIDs)

• patients receiving medical therapies considered to result in tolerance to opioids

• patients with a history of established chronic pain, (e.g. chronic low back pain, fibromyalgia or headaches), defined as requiring regular medical follow-up with pain specialists, as well as recent use (within the year preceding pregnancy) of opioid analgesics as an outpatient

• patients with a history of diabetes mellitus

• patients undergoing a vertical midline skin incision

• patients who are undergoing a cesarean delivery after a failed vaginal trial of labor

• patients who had a prior epidural placed for labor analgesia during the same hospital encounter.